US Food and Drug Administration (FDA) announced a major change to the mifepristone (Mifeprex) label.
Below please find a summary to the label changes, which include: the use of 200 mg mifepristone and 800 mcg misoprostol through 70 days gestation; home administration of misoprostol; and follow-up which does not require an in-clinic visit. Furthermore, the medicine may be prescribed by a healthcare provider, rather than a physician only. Included are also links for further information.
- FDA label change: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf
- Statement from American Congress of Obstetricians and Gynecologists: http://www.acog.org/About-ACOG/News-Room/Statements/2016/ACOG-Statement-on-Medication-Abortion